Fennec Pharmaceuticals (FENC) Tops Q4 EPS by 7c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.92 million versus the consensus estimate of $7.88 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Texas AG Paxton announces ongoing investigation into Carnival over data breach
• OpenAI launches open-source security program with Trail of Bits